Incidence of grade II-IV acute graft-versus-host disease (aGVHD) in nonmyeloablative
(NMA) transplant recipients remains high. To date, the ideal prophylaxis regimen, which …

Combined direct antineoplastic activity and the long-lasting immunological effects of
allogeneic hematopoietic cell transplant (HCT) can cure many hematological malignancies …

Tacrolimus (Tac) plus methotrexate (MTX) is a standard regimen for graft-versus-host
disease (GVHD) prophylaxis. Mycophenolate mofetil (MMF) is sometimes used instead of …

The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease
(GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem …

Background In patients undergoing allogeneic hematopoietic stem-cell transplantation
(HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against …

Both acute and chronic graft-versus-host disease (GVHD) are major causes of morbidity and
mortality in patients undergoing allogeneic hematopoietic stem cell transplantation …

Allogeneic hematopoietic cell transplant (HCT) remains the only curative therapy for many
hematologic malignancies but it is limited by high nonrelapse mortality (NRM), primarily from …

Graft-versus-host disease (GVHD), both acute and chronic, is still a leading cause of
nonrelapse mortality after transplantation. 1 Highdose, posttransplantation …

Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in renal
and heart transplant recipients, was used in combination with cyclosporin A (CsA) …

The standard regimens for graft-versus-host disease (GvHD) prophylaxis in matched
unrelated donor (MUD) transplantation were based on antithymocyte globulin (ATG) in …